Literature DB >> 7943573

Low prevalence of human T lymphotropic virus type I in !Kung San in Bushmanland, Namibia.

A D Steele1, P Bos, J J Joubert, A C Evans, S Joseph, L Tucker, S Aspinall, G Lecatsas.   

Abstract

Antibodies to human immunodeficiency virus 1 (HIV-1) and human T lymphotropic virus type 1 (HTLV-I) have been identified in various population groups living in southern and central Africa. Sera from 291 !Kung Bushmen in Bushmanland, Namibia were examined for the presence of antibodies to HIV-1 and HIV-2 and to HTLV-I. Initial screening for HIV-1/2 by two enzyme-linked immunosorbent assays (ELISAs) revealed evidence of past exposure in four individuals. However, no HIV-1/2 infection could be confirmed by a particle agglutination assay, a recombinant ELISA, or by Western blot for HIV-1 and HIV-2. Indeterminate Western blot profiles (with a p55 for each and either a p25 or p18 band) existed for all four HIV-1-reactive sera. Eight sera were reactive in the HTLV-I ELISA, although only five were positive on a second ELISA. Only three of the five HTLV-I-reactive sera could be confirmed by Western blot.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943573

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  2 in total

1.  Seroprevalence and correlates of human T-cell lymphoma/leukemia virus type 1 antibodies among pregnant women at the University of Nigeria Teaching Hospital, Enugu, Nigeria.

Authors:  Augustine Ejike Okoye; Obike Godswill Ibegbulam; Robinson Chukwudi Onoh; Paul Olisaemeka Ezeonu; Ngozi I Ugwu; Lucky Osaheni Lawani; Chukwudi Simon Anigbo; Charles E Nonyelu
Journal:  Int J Womens Health       Date:  2014-09-18

Review 2.  Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa.

Authors:  James M Fox; Nora Mutalima; Elizabeth Molyneux; Lucy M Carpenter; Graham P Taylor; Martin Bland; Robert Newton; Fabiola Martin
Journal:  Trop Med Int Health       Date:  2016-02-03       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.